One of KaloCyte’s co-founders, Dr. Allan Doctor, was among several experts interviewed for and quoted in the article on synthetic blood research, and KaloCyte’s ErythroMer and developmental status is featured

BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling KaloCyte to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and funding.

The University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state, including KaloCyte, with the $10 million Maryland Momentum Fund (MMF).

Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer.

Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions.

Elaine Haynes, president and CEO of KaloCyte, will join more than 800 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network.

The NIH SBIR grant will help KaloCyte develop ErythroMer™ to preclinical safety and efficacy testing.

KaloCyte co-founders Allan Doctor and Dipanjan Pan are featured in an article titled, “Making and storing blood to save lives”

KaloCyte welcomes Product Development Scientist, Nivesh Mittal, PhD to propel production of ErythroMer™

Elaine E. Haynes, President and CEO of KaloCyte, Inc., featured in BioSpace article touting Maryland, a BioCapital hotbed.